论文信息 - Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study - 字舞流文

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

S. Bhatt | S. Flaxman | W. Hinsley | E. Volz | A. Ghani | N. Ferguson | A. Charlett | A. Presanis | D. De Angelis | S. Funk | S. Seaman | S. Abbott | N. Andrews | J. L. Bernal | Katie Harman | J. Lopez Bernal | R. Hope | M. Kall | G. Dabrera | N. Andrews | S. Nash | A. Charlett | M. Chand | P. Blomquist | T. Nyberg | A. Zaidi | S. Thelwall | Harriet H Webster | Nurin Abdul Aziz | Nur Adilah Abdul Aziz | K. Harman | H. Webster | N. A. Aziz | Andre Charlett | Wes Hinsley | Meaghan Kall | Paula Blomquist | Anne M Presanis | Simon Thelwall | N. A. Abdul Aziz

[1] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[2] N. Daneman,et al. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. , 2022, JAMA.

[3] Frances E. Muldoon,et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.

[4] L. Poon,et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo , 2022, Nature.

[5] J. P. Almeida,et al. Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) , 2022, medRxiv.

[6] T. House,et al. OMICRON-ASSOCIATED CHANGES IN SARS-COV-2 SYMPTOMS IN THE UNITED KINGDOM , 2022, medRxiv.

[7] N. Volkow,et al. COVID infection severity in children under 5 years old before and after Omicron emergence in the US , 2022, medRxiv.

[8] M. Mendelson,et al. Outcomes of laboratory‐confirmed SARS‐CoV‐2 infection in the Omicron‐driven fourth wave compared with previous waves in the Western Cape Province, South Africa , 2022, medRxiv.

[9] M. Lipsitch,et al. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California , 2022, medRxiv.

[10] J. Starrfelt,et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11] J. Bhiman,et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.

[12] S. Kenny,et al. Clinical Characteristics of SARS-CoV-2 Omicron Infection in Children under One Year , 2022, SSRN Electronic Journal.

[13] P. Rheeder,et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa , 2021, International Journal of Infectious Diseases.

[14] William T. Harvey,et al. Genomic reconstruction of the SARS-CoV-2 epidemic in England , 2021, Nature.

[15] D. Fisman,et al. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada , 2021, Canadian Medical Association Journal.

[16] J. Wohlfahrt,et al. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark , 2021, The Lancet Infectious Diseases.

[17] A. Presanis,et al. Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic , 2021, medRxiv.

[18] Joshua B. Singer,et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study , 2021, The Lancet Infectious Diseases.

[19] Ross J. Harris,et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis , 2021, BMJ.

[20] J. Wohlfahrt,et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study , 2021, The Lancet Infectious Diseases.

[21] A. Sheikh,et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.

[22] K. Twohig,et al. Timeliness and completeness of laboratory-based surveillance of COVID-19 cases in England , 2021, Public Health.

[23] Susan Hopkins,et al. Healthcare-associated COVID-19 in England: A national data linkage study , 2021, Journal of Infection.

[24] S. Karim,et al. Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave , 2021, SSRN Electronic Journal.

[25] W. Hinsley,et al. Report 50: Hospitalisation risk for Omicron cases in England , 2021 .

[26] M. Miller. Agency , 2010 .